Eckert & Ziegler and Nucleus RadioPharma have signed extensive supply agreements for major therapeutic radioisotopes.
 
Under the terms of the agreements, Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form. Nucleus will use the radioisotopes to complement and advance its services for clinical development and manufacturing of radiopharmaceuticals.

Why Actinium-225 and Lutetium-177?

Actinium-225 and Lutetium-177 are used as radioactive substances in cancer treatment, emitting alpha (Ac-225) and beta (Lu-177) particles to destroy tumor cells. While Lu-177-based drug products have been approved for different indications and show increasing global demand, dozens of clinical studies are ongoing for both radioisotopes. According to market experts, the demand for Ac-225 will significantly increase over the next decade.
 
“We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply, and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler. “The collaboration and the growing demand for these novel radiopharmaceuticals prove the validity of our strategic investments in radioisotope production facilities.”
 
“The reliable supply with Ac-225 and Lu-177 is a major prerequisite to address the increasing need for radiopharmaceutical development and manufacturing,” explained Charles S. Conroy, CEO of Nucleus. “Our agreement with Eckert & Ziegler will enable us to advance our programs most efficiently and to secure patient access to innovative radiotherapies.”
 
While Eckert & Ziegler has successfully established a GMP-compliant production for Lu-177 in 2023 and is steadily upscaling the capacities, the manufacturing of larger quantities of GMP-grade Ac-225 is expected to start in 2024.

More Nucleus RadioPharma News

Nucleus RadioPharma recently reported a $56 million Series A funding round, which will fund new manufacturing facilities around the US.
 
Also, the company appointed Kathy Spencer-Pike chief commercial officer.